Coronavirus, CytoDyn, and You!

It’s May of 2020. We all know what Coronavirus is and how dangerous it can be. We also know that there’s a race in the US, and around the world, frankly, to find treatments, a cure, and a vaccine.

According to an article from targetedonc.com :

Leronlimab (PRO 140) demonstrated promising results in 49 patients with coronavirus disease 2019 (COVID-19) who received the CCR5 antagonist as treatment under the FDA’s emergency Investigational New Drug (eIND) program, according to a press release from CytoDyn, developer of the drug.

Leronlimab is a drug used to treat HIV, yet studies conducted by CytoDyn Inc (CYDY) show cautiously optimistic results, and that’s certainly a step in the right direction.

CytoDyn hopes to release a second paper regarding the results of administering Leronlimab to Covid-19 patients later this month, and that could mean that CYDY stock will grow.

According to Globe Newswire:

CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic…